Mobile

An Open-Label, Multicenter, Randomized, Phase Ib/II Study of E7080 in Combination with Carboplatin + Gemcitabine versus Carboplatin + Gemcitabine Alone as Second Line Therapy in Patients with Platinum...

Mise à jour : Il y a 4 ans
Référence : EUCTR2009-016050-41

An Open-Label, Multicenter, Randomized, Phase Ib/II Study of E7080 in Combination with Carboplatin + Gemcitabine versus Carboplatin + Gemcitabine Alone as Second Line Therapy in Patients with Platinum-Sensitive Recurrent Ovarian Cancer by CA125

Femme Homme

  • | Pays :
    • -
  • | Organes :
    • -
  • | Spécialités :
    • -

Extrait

• Phase Ib: to define the maximum tolerated dose (MTD)/ recommended Phase II of E7080 administered in combination with carboplatin + gemcitabine in patients with platinum-sensitive recurrent ovarian cancer. • Phase II: to evaluate the safety and tolerability of E7080 administered in combination with carboplatin + gemcitabine, compared with carboplatin + gemcitabine alone, in patients with platinum-sensitive recurrent ovarian cancer.

Critère d'inclusion

  • Platinum sensitive recurrent ovarian cancer

Liens